NCT05879614View on ClinicalTrials.gov

An Open-Label Study of Oral NNZ-2591 in Prader-Willi Syndrome (PWS-001)

PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

September 1, 2023

Primary Completion Date

June 30, 2025

Study Completion Date

June 30, 2025

Conditions
Prader-Willi Syndrome
Interventions
DRUG

NNZ-2591

NNZ-2591 oral solution (50mg/mL) to be administered twice daily for 13 weeks.

Trial Locations (4)

19063

Suburban Research, Media

20815

Uncommon Cures, Chevy Chase

30329

Rare Disease Research, Atlanta

92123

Rady Children's Hospital San Diego, San Diego

Sponsors
All Listed Sponsors
lead

Neuren Pharmaceuticals Limited

INDUSTRY

NCT05879614 - An Open-Label Study of Oral NNZ-2591 in Prader-Willi Syndrome (PWS-001) | Biotech Hunter | Biotech Hunter